GlaxoSmithKline (LON:GSK) Rating Reiterated by JPMorgan Chase & Co.

GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating restated by investment analysts at JPMorgan Chase & Co. in a report released on Friday, Digital Look reports.

Other analysts have also recently issued reports about the stock. Barclays lifted their price objective on shares of GlaxoSmithKline from GBX 1,400 ($19.00) to GBX 1,600 ($21.72) and gave the company an “equal weight” rating in a research note on Friday, November 5th. The Goldman Sachs Group set a GBX 2,000 ($27.15) price objective on shares of GlaxoSmithKline in a research note on Friday, January 7th. Credit Suisse Group set a GBX 1,400 ($19.00) target price on shares of GlaxoSmithKline in a research note on Thursday, October 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,350 ($18.32) target price on shares of GlaxoSmithKline in a research note on Wednesday, January 5th. Finally, Kepler Capital Markets set a GBX 1,500 ($20.36) target price on shares of GlaxoSmithKline in a research note on Thursday, October 28th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of GBX 1,591.80 ($21.61).

Shares of LON GSK opened at GBX 1,641 ($22.28) on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 117.74. GlaxoSmithKline has a 12 month low of GBX 1,190.80 ($16.16) and a 12 month high of GBX 1,650.60 ($22.41). The company has a 50 day simple moving average of GBX 1,583.52 and a two-hundred day simple moving average of GBX 1,489.71. The stock has a market cap of £82.57 billion and a price-to-earnings ratio of 19.24.

In other GlaxoSmithKline news, insider Hal Barron bought 2,422 shares of the company’s stock in a transaction dated Monday, November 22nd. The stock was acquired at an average price of GBX 2,065 ($28.03) per share, with a total value of £50,014.30 ($67,889.64).

About GlaxoSmithKline

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading: Why are analyst ratings important in trading stocks?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.